These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22615811)

  • 1. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
    Jiang Y; Cui L; Chen WD; Shen SH; Ding LD
    PLoS One; 2012; 7(5):e36780. PubMed ID: 22615811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
    Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
    PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
    Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
    Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis.
    Wang J; Wang B; Chen X; Bi J
    Carcinogenesis; 2011 Mar; 32(3):411-6. PubMed ID: 21156971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis.
    Chen C; Zhu Y; Zhang H; Xiao L
    Gynecol Obstet Invest; 2024; 89(5):363-375. PubMed ID: 38615670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
    Sheng X; Guo Y; Lu Y
    Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
    Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
    Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
    Wen G; Wang H; Zhong Z
    Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: A meta-analysis of prospective studies.
    Hu H; Zhou Y; Zhang M; Ding R
    Biomarkers; 2019 May; 24(3):207-216. PubMed ID: 30764677
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of RASSF1A promoter methylation with gastric cancer risk: a meta-analysis.
    Shi DT; Han M; Gao N; Tian W; Chen W
    Tumour Biol; 2014 Feb; 35(2):943-8. PubMed ID: 23982879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter Methylation of BRCA1, DAPK1 and RASSF1A is Associated with Increased Mortality among Indian Women with Breast Cancer.
    Yadav P; Masroor M; Nandi K; Kaza RCM; Jain SK; Khurana N; Saxena A
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):443-448. PubMed ID: 29480000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
    Yang J; Niu H; Huang Y; Yang K
    PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
    Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
    PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
    Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
    PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
    Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
    Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of RASSF1A promoter methylation in operable breast cancer.
    Kioulafa M; Kaklamanis L; Mavroudis D; Georgoulias V; Lianidou ES
    Clin Biochem; 2009 Jul; 42(10-11):970-5. PubMed ID: 19374895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of RASSF1A promoter methylation with lung cancer risk: a meta-analysis.
    Huang YZ; Wu W; Wu K; Xu XN; Tang WR
    Asian Pac J Cancer Prev; 2014; 15(23):10325-8. PubMed ID: 25556469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of RASSF1A gene methylation on clinico-pathological features of tumor and non-tumor tissue of breast cancer.
    Gupta V; Agarwal P; Deshpande P
    Ann Diagn Pathol; 2021 Jun; 52():151722. PubMed ID: 33621744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Ras association domain family 1A promoter methylation and esophageal squamous cell carcinoma: a meta-analysis.
    Yang JZ; Ji AF; Wang JS; Chen ZY; Wen SW
    Asian Pac J Cancer Prev; 2014; 15(9):3921-5. PubMed ID: 24935575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
    Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
    Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.